Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00553332 · ClinicalTrials.gov registry record · Phase 2
Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By Surgery
A Phase 2 study of Liver and Intrahepatic Biliary Tract Cancer and Recurrent Extrahepatic Bile Duct Cancer, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
- 7
- Study locations
NCT00553332: Completed Phase 2 study of Liver and Intrahepatic Biliary Tract Cancer and Recurrent Extrahepatic Bile Duct Cancer, sponsored by National Cancer Institute (NCI).
NCT00553332 is a Phase 2 study of Liver and Intrahepatic Biliary Tract Cancer and Recurrent Extrahepatic Bile Duct Cancer that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 29 participants. The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00553332, a Phase 2 study of Liver and Intrahepatic Biliary Tract Cancer and Recurrent Extrahepatic Bile Duct Cancer, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
- 7
- Study locations
Study Summary
This phase II trial is studying how well selumetinib works in treating patients with biliary cancer that cannot be removed by surgery. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- DRUG selumetinib
Study Locations (7)
Michigan
- University of Michigan Cancer Center (UMCC) Research Base - Ann Arbor
- Wayne State University - Detroit
Florida
- H. Lee Moffitt Cancer Center and Research Institute - Tampa
Georgia
- Emory University - Atlanta
North Carolina
- University of North Carolina - Chapel Hill
Ohio
- Ohio State University Medical Center - Columbus
Tennessee
- Vanderbilt University - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2007-11 |
| Est. Completion | 2013-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00553332
The ClinicalTrials.gov registry entry for NCT00553332 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Liver and Intrahepatic Biliary Tract Cancer appearing as the primary indexed condition, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT00553332 reports 7 study locations spanning 6 distinct geographic areas - top geographies include Michigan, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT00553332 about?
NCT00553332 is a clinical study titled "Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By Surgery". This phase II trial is studying how well selumetinib works in treating patients with biliary cancer that cannot be removed by surgery. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT00553332?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2007-11. Estimated completion is 2013-01.
What conditions does trial NCT00553332 study?
This clinical trial studies the following conditions: Liver and Intrahepatic Biliary Tract Cancer, Recurrent Extrahepatic Bile Duct Cancer, Unresectable Extrahepatic Bile Duct Cancer.
What interventions are being tested in trial NCT00553332?
The interventions under investigation include: laboratory biomarker analysis (OTHER), selumetinib (DRUG).
Who is sponsoring clinical trial NCT00553332?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00553332 being conducted?
This trial has 7 study locations across Florida, Georgia, Michigan, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Liver and Intrahepatic Biliary Tract Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Liver and Intrahepatic Biliary Tract Cancer
All registered trials for this condition
Recurrent Extrahepatic Bile Duct Cancer
All registered trials for this condition
Florida
All trials with a study site in Florida
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.